Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system
Open accessAbstract
Prolonged exposure to drugs of abuse, such as cannabinoids and opioids, leads to pharmacological tolerance and receptor desensitization in the nervous system. We found that a similar form of functional antagonism was produced by sustained inactivation of monoacylglycerol lipase (MAGL), the principal degradative enzyme for the endocannabinoid 2-arachidonoylglycerol. After repeated administration, the MAGL inhibitor JZL184 lost its analgesic activity and produced cross-tolerance to cannabinoid receptor (CB1) agonists in mice, effects that were phenocopied by genetic disruption of Mgll (encoding MAGL). Chronic MAGL blockade also caused physical dependence, impaired endocannabinoid-dependent synaptic plasticity and desensitized brain CB1 receptors. These data contrast with blockade of fatty acid amide hydrolase, an enzyme that degrades the other major endocannabinoid anandamide, which produced sustained analgesia without impairing CB1 receptors. Thus, individual endocannabinoids generate distinct analgesic profiles that are either sustained or transitory and associated with agonism and functional antagonism of the brain cannabinoid system, respectively.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Chronic high-dose MAGL inhibition desensitizes CB1R and produces a phenotype more akin to CB1R antagonism than agonism.
“the ability of chronic, high-dose MAGL inhibition to desensitize the CB1R and produce a phenotype that is more akin to CB1R antagonism than agonism (Schlosburg et al., 2010; Schlosburg et al., 2014).”
From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Schlosburg et al., 2010
The development and expression of neuropathic pain were not modified in FAAH or MAGL-/- mice.
“On the other hand, the development and expression of neuropathic pain were not modified in FAAH or MAGL ( -/ -) mice (Nadal et al, 2013;Schlosburg et al, 2010).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Schlosburg et al, 2010
Repeated administration of a high dose of the MAGL inhibitor JZL184 leads to tolerance, largely due to CB1 receptor downregulation and desensitization.
“In contrast, repeated administration of a high dose of the MAGL inhibitor JZL184 leads to tolerance, largely due to CB 1 receptor downregulation and desensitization (Schlosburg et al, 2010).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Schlosburg et al, 2010
FAAH inhibitors produce antinociceptive effects in the CCI model without the development of tolerance upon repeated administration.
“It is noteworthy that FAAH inhibitors produce antinociceptive effects in the CCI model, without the development of tolerance upon repeated administration (Schlosburg et al, 2010).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Schlosburg et al, 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633 · see citing works
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913 · see citing works
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196 · see citing works
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125 · see citing works
Self-citationThe Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077 · see citing works
Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310 · see citing works
Self-citationModulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293 · see citing works
Endocannabinoid Signaling in the Brain
Wilson, R. I., & Nicoll, R. A. (2002) · Science · doi:10.1126/science.1063545 · Cited by 1,260 · see citing works
CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity
Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G., Gutiérrez, S. O., van der Stelt, M., et al. (2003) · Science · doi:10.1126/science.1088208 · Cited by 1,208 · see citing works
A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol
Blankman, J. L., Simon, G. M., & Cravatt, B. F. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.11.006 · Cited by 1,177 · see citing works
Self-citationActivity-based protein profiling: The serine hydrolases
Liu, Y., Patricelli, M. P., & Cravatt, B. F. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14694 · Cited by 1,133 · see citing works
Self-citationSelective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects
Long, J. Z., Li, W., Booker, L., Burston, J. J., Kinsey, S. G., Schlosburg, J. E., Pavón, F. J., Serrano, A., Selley, D. E., Parsons, L. H., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.129 · Cited by 938 · see citing works
Self-citationOhno‐Shosaku, T., Maejima, T., & Kano, M. (2001) · Neuron · doi:10.1016/s0896-6273(01)00247-1 · Cited by 846 · see citing works
Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist
Deutsch, D. G., & Chin, S. A. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90486-g · Cited by 705 · see citing works
Presynaptic Specificity of Endocannabinoid Signaling in the Hippocampus
Wilson, R. I., Kunos, G., & Nicoll, R. A. (2001) · Neuron · doi:10.1016/s0896-6273(01)00372-5 · Cited by 543 · see citing works
Enzymatic pathways that regulate endocannabinoid signaling in the nervous system
Ahn, K., McKinney, M. K., & Cravatt, B. F. (2008) · Chemical Reviews · doi:10.1021/cr0782067 · Cited by 529 · see citing works
Self-citationCANNABINOID RECEPTORS AS THERAPEUTIC TARGETS
Mackie, K. (2005) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141254 · Cited by 508 · see citing works
Gao, Y., Vasilyev, D. V., Goncalves, M. B., Howell, F. V., Hobbs, C., Reisenberg, M., Shen, R., Zhang, M.-Y., Strassle, B. W., Lu, P., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5693-09.2010 · Cited by 473 · see citing works
Tanimura, A., Yamazaki, M., Hashimotodani, Y., Uchigashima, M., Kawata, S., Abe, M., Kita, Y., Hashimoto, K., Shimizu, T., Watanabe, M., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.01.021 · Cited by 472 · see citing works
Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain
Ahn, K., Johnson, D. S., Mileni, M., Beidler, D., Long, J. Z., McKinney, M. K., Weerapana, E., Sadagopan, N., Liimatta, M., Smith, S. E., et al. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.02.013 · Cited by 439 · see citing works
Self-citationLong, J. Z., Nomura, D. K., Vann, R. E., Walentiny, D. M., Booker, L., Jin, X., Burston, J. J., Sim‐Selley, L. J., Lichtman, A. H., Wiley, J. L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909411106 · Cited by 393 · see citing works
Self-citationBlockade of Endocannabinoid-Degrading Enzymes Attenuates Neuropathic Pain
Kinsey, S. G., Long, J. Z., O’Neal, S. T., Abdullah, R. A., Poklis, J. L., Boger, D. L., Cravatt, B. F., & Lichtman, A. H. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.155465 · Cited by 330 · see citing works
Self-citationLichtman, A. H., Leung, D., Shelton, C. C., Saghatelian, A., Hardouin, C., Boger, D. L., & Cravatt, B. F. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.069401 · Cited by 329 · see citing works
Self-citationSim, L. J., Hampson, R. E., Deadwyler, S. A., & Childers, S. R. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-24-08057.1996 · Cited by 311 · see citing works
Long, J. Z., Nomura, D. K., & Cravatt, B. F. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.05.009 · Cited by 305 · see citing works
Self-citationLichtman, A. H., Shelton, C. C., Advani, T., & Cravatt, B. F. (2004) · Pain · doi:10.1016/j.pain.2004.01.022 · Cited by 301 · see citing works
Self-citationCaillé, S., Alvarez-Jaimes, L., Polis, I., Stouffer, D. G., & Parsons, L. H. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4403-06.2007 · Cited by 280 · see citing works
Lichtman, A. H., Cook, S. A., & Martin, B. R. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12310-0 · Cited by 261 · see citing works
Self-citationHillard, C. J. (2000) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(00)00051-4 · Cited by 255 · see citing works
Genetic Dissection of Behavioural and Autonomic Effects of Δ9-Tetrahydrocannabinol in Mice
Monory, K., Blaudzun, H., Massa, F., Kaiser, N., Lemberger, T., Schütz, G., Wotjak, C. T., Lutz, B., & Marsicano, G. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050269 · Cited by 241 · see citing works
Lichtman, A. H., Hawkins, E. G., Griffin, G., & Cravatt, B. F. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.302.1.73 · Cited by 224 · see citing works
Self-citationRetrograde signaling by endocannabinoids
Kreitzer, A. C. (2002) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(02)00328-8 · Cited by 220 · see citing works
Pan, B., Wang, W., Long, J. Z., Sun, D., Hillard, C. J., Cravatt, B. F., & Liu, Q.-S. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.158162 · Cited by 165 · see citing works
Self-citationAnalgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain
Jhaveri, M. D., Richardson, D., Kendall, D. A., Barrett, D. A., & Chapman, V. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3326-06.2006 · Cited by 159 · see citing works
Haller, J., Barna, I., Barsvari, B., Gyimesi Pelczer, K., Yasar, S., Panlilio, L. V., & Goldberg, S. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1494-7 · Cited by 159 · see citing works
Romero, J., García‐Palomero, E., Castro, J. G., Garcı́a-Gil, L., Ramos, J. A., & Fernández‐Ruíz, J. (1997) · Molecular Brain Research · doi:10.1016/s0169-328x(96)00277-x · Cited by 147 · see citing works
Cannabinoid Tolerance and Dependence
Lichtman, A. H., & Martin, B. R. (2005) · Springer eBooks · doi:10.1007/3-540-26573-2_24 · Cited by 142 · see citing works
Self-citationCannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A
Aceto, M. D. G., Scates, S. M., Lowe, J. A., III, & Martin, B. R. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00447-s · Cited by 131 · see citing works
Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212.
Fan, F., Compton, D. M., Ward, S. J., Melvin, L. S., & Martin, B. R. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24023-x · Cited by 126 · see citing works
Sim‐Selley, L. J., & Martin, B. R. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035618 · Cited by 125 · see citing works
Self-citationSchlosburg, J. E., Carlson, B. L. A., Ramesh, D., Abdullah, R. A., Long, J. Z., Cravatt, B. F., & Lichtman, A. H. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9110-7 · Cited by 119 · see citing works
Self-citationActivation of the endocannabinoid system by organophosphorus nerve agents
Nomura, D. K., Blankman, J. L., Simon, G. M., Fujioka, K., Issa, R. S., Ward, A. M., Cravatt, B. F., & Casida, J. E. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.86 · Cited by 112 · see citing works
Self-citationLuk, T., Jin, W., Zvonok, A. M., Lu, D., Lin, X., Chavkin, C., Makriyannis, A., & Mackie, K. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705792 · Cited by 99 · see citing works
Straiker, A. J., Hu, S. S., Long, J. Z., Arnold, A., Wager‐Miller, J., Cravatt, B. F., & Mackie, K. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.059030 · Cited by 97 · see citing works
Self-citationPertwee, R. G., & Wickens, A. P. (1991) · Neuropharmacology · doi:10.1016/0028-3908(91)90150-a · Cited by 87 · see citing works
Falenski, K. W., Thorpe, A. J., Schlosburg, J. E., Cravatt, B. F., Abdullah, R. A., Smith, T. H., Selley, D. E., Lichtman, A. H., & Sim‐Selley, L. J. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.44 · Cited by 83 · see citing works
Self-citation正幸, 大., Danielson, P. E., Nelson, P. A., Pribyl, T. M., Hilbush, B. S., Hasel, K. W., & Sutcliffe, J. G. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00027.x · Cited by 63 · see citing works
Fowler, C. J. (2006) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2006.00442.x · Cited by 57 · see citing works
Lanoir, J., Hilaire, G., & Seif, I. (2006) · The Journal of Comparative Neurology · doi:10.1002/cne.20916 · Cited by 23 · see citing works
Sun, M., Lee, C. J., & Shin, H. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.120147 · Cited by 20 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Endocannabinoid Hydrolysis Generates Brain Prostaglandins That Promote Neuroinflammation
Nomura, D. K., Morrison, B. E., Blankman, J. L., Long, J. Z., Kinsey, S. G., Marcondes, M. C. G., Ward, A. M., Hahn, Y. K., Lichtman, A. H., Conti, B., et al. (2011) · Science · doi:10.1126/science.1209200 · Cited by 727 · see citing works
Self-citationMultiple Functions of Endocannabinoid Signaling in the Brain
Katona, I., & Freund, T. F. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-062111-150420 · Cited by 630 · see citing works
The endocannabinoid system in guarding against fear, anxiety and stress
Lutz, B., Marsicano, G., Maldonado, R., & Hillard, C. J. (2015) · Nature reviews. Neuroscience · doi:10.1038/nrn4036 · Cited by 506 · see citing works
Chemical Probes of Endocannabinoid Metabolism
Blankman, J. L., & Cravatt, B. F. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006387 · Cited by 327 · see citing works
Self-citationGunduz-Cinar, O., MacPherson, K. P., Cinar, R., Gamble-George, J., Sugden, K., Williams, B., Godlewski, G., Ramikie, T. S., Gorka, A. X., Alapafuja, S. O., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.72 · Cited by 307 · see citing works
Donvito, G., Nass, S. R., Wilkerson, J. L., Curry, Z. A., Schurman, L. D., Kinsey, S. G., & Lichtman, A. H. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.204 · Cited by 301 · see citing works
Self-citationDifferential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses
Busquets-Garcia, A., Puighermanal, E., Pastor, A., de la Torre, R., Maldonado, R., & Ozaita, A. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.022 · Cited by 273 · see citing works
The endocannabinoid system as a target for novel anxiolytic drugs
Patel, S., Hill, M. N., Cheer, J. F., Wotjak, C. T., & Holmes, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.033 · Cited by 233 · see citing works
Amygdala FAAH and anandamide: mediating protection and recovery from stress
Gunduz-Cinar, O., Hill, M. N., McEwen, B. S., & Holmes, A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.08.008 · Cited by 229 · see citing works
Piro, J. R., Benjamin, D. I., Duerr, J. M., Pi, Y., Gonzales, C., Wood, K. M., Schwartz, J. W., Nomura, D. K., & Samad, T. A. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.05.001 · Cited by 223 · see citing works
Self-citationGoods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years
Maccarrone, M., Di Marzo, V., Gertsch, J., Grether, U., Howlett, A. C., Hua, T., Makriyannis, A., Piomelli, D., Ueda, N., & van der Stelt, M. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000600 · Cited by 183 · see citing works
Sciolino, N. R., Zhou, W., & Hohmann, A. G. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.04.010 · Cited by 179 · see citing works
Lipids in Psychiatric Disorders and Preventive Medicine
Schneider, M., Levant, B., Reichel, M., Gulbins, E., Kornhuber, J., & Müller, C. P. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.002 · Cited by 175 · see citing works
Kinsey, S. G., Wise, L. E., Ramesh, D., Abdullah, R., Selley, D. E., Cravatt, B. F., & Lichtman, A. H. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201426 · Cited by 169 · see citing works
Self-citationAnxiety, stress, and fear response in mice with reduced endocannabinoid levels
Jenniches, I., Ternes, S., Albayram, O., Otte, D. M., Bach, K., Bindila, L., Michel, K., Lutz, B., Bilkei-Gorzo, A., & Zimmer, A. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.03.033 · Cited by 169 · see citing works
Evaluation of NHS Carbamates as a Potent and Selective Class of Endocannabinoid Hydrolase Inhibitors
Niphakis, M. J., Cognetta, A. B., Chang, J. W., Buczynski, M. W., Parsons, L. H., Byrne, F., Burston, J. J., Chapman, V., & Cravatt, B. F. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400116z · Cited by 157 · see citing works
Self-citationSchiavon, A. P., Bonato, J. M., Milani, H., Guimarães, F. S., & Weffort de Oliveira, R. M. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.06.017 · Cited by 135 · see citing works
Lee, S.-H., Ledri, M., Toth, B., Marchionni, I., Henstridge, C. M., Dudok, B., Kenesei, K., Barna, L., Szabo, S. I., Renkecz, T., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.4112-14.2015 · Cited by 133 · see citing works
More surprises lying ahead. The endocannabinoids keep us guessing
Piomelli, D. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.026 · Cited by 128 · see citing works
Ignatowska‐Jankowska, B. M., Ghosh, S., Crowe, M. S., Kinsey, S. G., Niphakis, M. J., Abdullah, R. A., Tao, Q., O' Neal, S. T., Walentiny, D. M., Wiley, J. L., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12298 · Cited by 128 · see citing works
Self-citationGhosh, S., Wise, L. E., Chen, Y., Gujjar, R., Mahadevan, A., Cravatt, B. F., & Lichtman, A. H. (2013) · Life Sciences · doi:10.1016/j.lfs.2012.06.020 · Cited by 127 · see citing works
Self-citationSumislawski, J. J., Ramikie, T. S., & Patel, S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.166 · Cited by 124 · see citing works
Endocannabinoids modulate cortical development by configuring Slit2/Robo1 signalling
Alpár, A., Tortoriello, G., Calvigioni, D., Niphakis, M. J., Milenkovic, I., Bakker, J., Cameron, G. A., Hanics, J., Morris, C. V., Fuzik, J., et al. (2014) · Nature Communications · doi:10.1038/ncomms5421 · Cited by 96 · see citing works
Self-citationInhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver
Habib, A., Chokr, D., Wan, J., Hegde, P., Mabire, M., Siebert, M., Ribeiro-Parenti, L., Le Gall, M., Lettéron, P., Pilard, N., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316137 · Cited by 91 · see citing works
Self-citationEndocannabinoid-mediated synaptic plasticity and addiction-related behavior
Sidhpura, N., & Parsons, L. H. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.034 · Cited by 92 · see citing works
Wilkerson, J. L., Ghosh, S., Mustafa, M., Abdullah, R. A., Niphakis, M. J., Cabrera, R., Maldonado, R. L., Cravatt, B. F., & Lichtman, A. H. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.11.015 · Cited by 78 · see citing works
Self-citationRole of the endocannabinoid system in the regulation of intestinal homeostasis
Cuddihey, H., MacNaughton, W. K., & Sharkey, K. A. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.05.015 · Cited by 79 · see citing works
Nadal, X., La Porta, C., Andreea Bura, S., & Maldonado, R. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.01.077 · Cited by 76 · see citing works
Ramikie, T. S., & Patel, S. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.037 · Cited by 62 · see citing works
Ghosh, S., Kinsey, S. G., Liu, Q.-S., Hruba, L., McMahon, L. R., Grim, T. W., Merritt, C. R., Wise, L. E., Abdullah, R. A., Selley, D. E., et al. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.222851 · Cited by 54 · see citing works
Self-citationJZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy
Khasabova, I. A., Yao, X., Paz, J., Lewandowski, C. T., Lindberg, A. E., Coicou, L., Burlakova, N., Simone, D. A., & Seybold, V. S. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.09.008 · Cited by 50 · see citing works
Nozaki, C., Markert, A., & Zimmer, A. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.04.001 · Cited by 45 · see citing works
Schlosburg, J. E., Kinsey, S. G., Ignatowska-Jankowska, B., Ramesh, D., Abdullah, R. A., Tao, Q., Booker, L., Long, J. Z., Selley, D. E., Cravatt, B. F., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.212753 · Cited by 44 · see citing works
Self-citationBurston, J. J., Mapp, P. I., Sarmad, S., Barrett, D. A., Niphakis, M. J., Cravatt, B. F., Walsh, D. A., & Chapman, V. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13574 · Cited by 30 · see citing works
Self-citationFeliszek, M., Bindila, L., Lutz, B., Zimmer, A., Bilkei-Gorzo, A., & Schlicker, E. (2016) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-016-1226-6 · Cited by 22 · see citing works
Guadalupi, L., Mandolesi, G., Vanni, V., Balletta, S., Caioli, S., Pavlovic, A., De Vito, F., Fresegna, D., Sanna, K., Vitiello, L., et al. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109940 · Cited by 22 · see citing works
- Authors
- Schlosburg, J. E., Blankman, J. L., Long, J. Z., Nomura, D. K., Pan, B., Kinsey, S. G., Nguyen, P. T., Ramesh, D., Booker, L., Burston, J. J., Thomas, E. A., Selley, D. E., Sim-Selley, L. J., Liu, Q.-S., Lichtman, A. H., & Cravatt, B. F.
- Affiliations
- Virginia Commonwealth University (US)
- Scripps Research Institute (US)
- Medical College of Wisconsin (US)
- Corresponding author
- Lichtman, Aron H
- Cravatt, Benjamin F
- ORCID
- Venue
- Nature Neuroscience
- Published
- 2010-08-22
- Volume
- 13
- Issue
- 9
- Pages
- 1113-1119
- ISSN
- 1097-6256 (ISSN-L)
- 1546-1726
- PMC
- PMC2928870
- OpenAlex
- W2163953252
- Cited by
- 641
- References
- 50
- Citations by year
- 2026: 26 · 2025: 30 · 2024: 29 · 2023: 30 · 2022: 39 · 2021: 47 · 2020: 38 · 2019: 23 · 2018: 42 · 2017: 42 · 2016: 32 · 2015: 61 · 2014: 57 · 2013: 47 · 2012: 39
- FWCI
- 33.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Funders
- National Institutes of Health
- National Institute on Drug Abuse (DA 07027, DA024741, DA023758, DA 015683, R37DA003672, DA026279, F31DA026279, DA014277, P01DA009789, R01DA014277, DA-017259, DA028333, R01DA015683, R01DA024741, DA‐03672, F30DA023758, F31DA028333, F31DA026261, DA025285, R01DA025285, P01DA017259, DA 009789, R01DA003672, DA026261, DA-005274, P50DA005274, T32DA007027)
- Topics
- Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- monoacylglycerol lipase, MAGL inhibition, JZL184, endocannabinoid system, 2-arachidonoylglycerol, cross-tolerance, analgesia, synaptic plasticity, physical dependence, fatty acid amide hydrolase, anandamide, drug tolerance, cannabinoid receptor agonists
- MeSH terms
- Fatty Acid Amide Hydrolases, Amidohydrolases, Analgesics, Animals, Brain, Enzyme Inhibitors, Female, Male, Mice, Inbred C57BL, Mice, Transgenic, Monoacylglycerol Lipases, Neuronal Plasticity, Pain, Piperidines, Synapses, Mice, Knockout, Models, Animal, Receptor, Cannabinoid, CB1, Mice, Benzodioxoles, Cannabinoid Receptor Modulators, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
